Brendan Smith

Insider Reports History

Entity
Individual
Location
29 Hartwell Avenue, Lexington, MA
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Brendan Smith:

Stock Role Class Num Shares Value Price $ Report Date Ownership
CRISPR Therapeutics AG Chief Financial Officer Common Shares 5.07K $317K $62.50 Feb 21, 2023 Direct
CRISPR Therapeutics AG Chief Financial Officer Stock Option (Right to Buy) 14K Oct 7, 2022 Direct
CRISPR Therapeutics AG Chief Financial Officer Restricted Stock Units 11.5K Feb 18, 2023 Direct
Translate Bio, Inc. Chief Financial Officer Stcok Option (right to buy) 0 Sep 14, 2021 Direct

Insider Reports Filed by Brendan Smith

Symbol Company Period Transactions Value $ Form Type Date Filed Role
CRSP CRISPR Therapeutics AG Feb 18, 2023 3 -$67.2K 4 Feb 22, 2023 Chief Financial Officer
CRSP CRISPR Therapeutics AG Oct 14, 2022 3 -$61.9K 4 Oct 18, 2022 Chief Financial Officer
CRSP CRISPR Therapeutics AG Oct 7, 2022 1 $0 4 Oct 12, 2022 Chief Financial Officer
CRSP CRISPR Therapeutics AG Aug 16, 2022 1 $0 4 Aug 18, 2022 Chief Financial Officer
CRSP CRISPR Therapeutics AG Feb 18, 2022 2 $0 4 Feb 22, 2022 Chief Financial Officer
CRSP CRISPR Therapeutics AG Oct 14, 2021 2 $0 4 Oct 18, 2021 Chief Financial Officer
CRSP CRISPR Therapeutics AG Oct 14, 2021 0 $0 3 Oct 15, 2021 Chief Financial Officer
TBIO Translate Bio, Inc. Sep 14, 2021 1 $0 4 Sep 14, 2021 Chief Financial Officer